Summary
GE HealthCare Technologies Inc. reported total revenues of $4.65 billion for the first quarter of 2024, a slight decrease of 1% compared to the prior year period, which was largely flat on an organic basis. This modest top-line performance was driven by mixed segment results, with the Pharmaceutical Diagnostics (PDx) segment showing strong growth, while Imaging, Ultrasound, and Patient Care Solutions (PCS) experienced declines. Despite the slight revenue dip, the company demonstrated improved profitability metrics. Operating income saw a slight decrease, but Adjusted EBIT and Adjusted Net Income increased by 3% and 6% respectively, indicating effective cost management and operational efficiencies. Diluted Earnings Per Share (EPS) significantly improved to $0.81 from $0.41 in the prior year, largely due to the absence of a large deemed preferred stock dividend related to redeemable noncontrolling interests in the prior year. The company maintained a strong liquidity position with $2.56 billion in cash and cash equivalents and access to substantial credit facilities, positioning it to fund operations and strategic initiatives, including a recent acquisition in April 2024.
Financial Highlights
47 data points| Revenue | $4.65B |
| Gross Profit | $1.90B |
| R&D Expenses | $324.00M |
| SG&A Expenses | $1.04B |
| Operating Expenses | $1.36B |
| Operating Income | $540.00M |
| Net Income | $374.00M |
| EPS (Basic) | $0.82 |
| EPS (Diluted) | $0.81 |
| Shares Outstanding (Basic) | 456.00M |
| Shares Outstanding (Diluted) | 459.00M |
Key Highlights
- 1Total revenues for Q1 2024 were $4.65 billion, a 1% decrease year-over-year, but flat organically, reflecting stable underlying business performance despite some segment headwinds.
- 2The Pharmaceutical Diagnostics (PDx) segment was a bright spot, showing 7% revenue growth year-over-year, driven by price increases, volume growth, and new product introductions.
- 3Diluted Earnings Per Share (EPS) significantly increased to $0.81 in Q1 2024, up from $0.41 in Q1 2023, largely due to the absence of a prior year noncontrolling interest dividend and improved operational performance.
- 4Adjusted EBIT and Adjusted Net Income showed positive growth, increasing by 3% and 6% respectively, indicating effective cost management and operational efficiency improvements.
- 5Remaining Performance Obligations (RPO) decreased by 2% to $14.31 billion, primarily due to fulfillment and cancellations outpacing new contracts and renewals.
- 6The company maintained a strong financial position with $2.56 billion in cash, cash equivalents, and restricted cash, and had no outstanding borrowings under its major revolving credit facilities.
- 7GE HealthCare completed the acquisition of MIM Software Inc. in April 2024 for approximately $258 million, aiming to strengthen its medical imaging analysis and AI solutions portfolio.